Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4147694 | 0.98 | ITGB3 (0.45) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A | |
| SCHEMBL4329812 | 0.83 | ITGB3 (0.49) | ITGB3ITGA2BSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL31752671 | 0.83 | KDM1A (0.48) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A | |
| Hydrochloric Acid SCHEMBL4139630 | 0.81 | TDP1 (0.50) | ITGB3ITGA2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12205066 | 0.81 | ITGB3 (0.46) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A | |
| Hydrochloric Acid SCHEMBL31753720 | 0.81 | PARP10 (0.59) | ITGB3ITGA2BCHEK2 | |
| SCHEMBL12719194 | 0.80 | ITGB3 (0.45) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A | |
| SCHEMBL4326032 | 0.80 | NPY1R (0.50) | ITGB3ITGA2BCHEK2NFE2L2TDP1 | |
| SCHEMBL4321291 | 0.79 | KDM4E (0.48) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A | |
| SCHEMBL13144596 | 0.79 | ITGB3 (0.46) | ITGB3ITGA2BSLC6A2SLC6A4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | ITGB3 2724/4885ITGA2B 2099/4885SLC6A2 1422/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | ITGB3 4464/4885ITGA2B 4258/4885SLC6A2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.